Events during the fourth quarter 2025
Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US
Leqembi was approved in Brazil and Canada
Leqembi was approved for IV maintenance treatment in the United Kingdom
Eisai submitted application for subcutaneous initiation treatment with Leqembi in Japan
New Leqembi data presented at CTAD 2025 suggested potential to delay disease progression by up to 8.3 years with continuous treatment
The first Nordic patient was treated with Leqembi at private clinic in Finland
Events after the end of the fourth quarter
BLA for subcutaneous initiation treatment with Leqembi was accepted and designated for priority review in China
Leqembi Iqlik sBLA for subcutaneous initiation dose was granted Priority Review by the US FDA
Eisai submitted a Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi
Financial summary October, December 2025
Net revenues amounted to SEK 184.0 M (101.2), of which SEK 127.0 M (96.7) in royalties for Leqembi and SEK 51.1 M (-) from the agreement with Novartis
Operating profit amounted to SEK 33.2 M (-53.5)
Profit for the period amounted to SEK -8.8 M (-31.5)
Earnings per share before and after dilution amounted to SEK -0.10 (-0.36)
Cash flow from operating activities amounted to SEK 313.3 M (-27.4)
Cash and cash equivalents and short-term investments at the end of the period amounted to SEK 2,190.4 M (778.9)
The Board of Directors proposes a dividend of 2.00 SEK per share to be paid for the financial year 2025
Comments from the CEO, '2025 was a record year for BioArctic, with an operating profit of more than SEK 1.2 billion'
2025 was a fantastic year for BioArctic, with record financial results, another partnership and new projects. We set a new course for the future and entered a new era, the growth era. For a long time, we have been building a solid foundation for the company's next phase of development, and I am proud of what we have achieved together with our employees and partners.
Leqembi is now approved in more than 50 markets and sales continue to grow every quarter. In the fourth quarter, our royalty revenues grew by 31 percent compared to the same quarter the year before, despite significant negative currency impact. In the US, Japan and China, the number of patients on treatment is steadily increasing. In Japan, despite solid demand, revenue in local currency was flat compared to the previous quarter in light of the 15 percent price reduction implemented in November. Similarly, China showed no significant revenue growth quarter-on-quarter as a consequence of the inventory build-up in the second quarter. Despite the impact of the above, Eisai is steadily progressing toward achieving their full-year sales forecast for Leqembi ...
